Details About Generic Salt ::  Methylpr

Main Medicine Class:: Corticosteroid   

(METH-ill-pred-NIH-suh-lone)

Medrol,  Depo-Medrol, Medrol Veriderm

Methylpredinisolone Sodium Succinate

A-Methapred, Solu-Medrol

Methylprednisolone Acetate

Adlone, depMedalone 40, depMedalone 80, Depoject, Depo-Medrol, Depopred-40, D-Med 80, Duralone-40, Duralone-80, Medralone-40, Medralone-80, Medrol Acetate Topical, M-Prednisol-40, M-Prednisol-80, Rep-Pred 40, Rep-Pred 80

Class: Corticosteroid

 

Drugs Class ::

 Action Depresses formation, release and activity of endogenous mediators of inflammation including prostaglandins, kinins, histamine, liposomal enzymes and complement system. Modifies body’s immune response.

Indications for Drugs ::

 Indications Replacement therapy in primary or secondary adrenal cortex insufficiency; djunctive therapy for short-term administration in rheumatic disorders; exacerbation or maintenance therapy in collagen diseases; treatment of dermatologic diseases; ontrol of allergic states or allergic and inflammatory ophthalmic processes; anagement of respiratory diseases; treatment of hematologic disorders; palliative management of neo-plastic diseases; management of cerebral edema associated with primary or metastatic brain tumor, craniotomy or head injury; induction of diuresis in edematous states (from nephrotic syndrome); management of critical exacerbations of GI diseases; management of acute exacerbations of multiple sclerosis; treatment of tuberculous meningitis; management of trichinosis with neurologic or myocardial involvement. Intra-articular or soft tissue administration: Adjunctive therapy for short-term administration in synovitis of osteoarthritis, rheumatoid arthritis, bursitis, acute gouty arthritis, epicondylitis, acute nonspecific tenosynovitis and posttraumatic osteoarthritis. Intralesional administration: Management of keloids; treatment of localized hypertrophic, infiltrated, inflammatory lesions of lichen planus, psoriatic plaques, granuloma annulare, lichen simplex chronicus; treatment of discoid lupus erythematosus, necrobiosis lipoidica diabeticorum, alopecia areata and cystic tumors of aponeurosis or tendon. Topical administration: Treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Unlabeled use(s): Reduction of mortality in severe alcoholic hepatitis; prevention of respiratory distress syndrome; treatment of septic shock; improvement of neurologic function in acute spinal cord injury.

Drug Dose ::

 Route/Dosage

METHYLPREDNISOLONE

ADULTS: PO 4–48 mg/day.

METHYLPREDNISOLONE SODIUM SUCCINATE

ADULTS: IV/IM 10–40 mg administered over 1 to several min. In severe condition, 30 mg/kg infused over 30 min; may repeat q 4–6 hr for 48–72 hr. INFANTS & CHILDREN: IV/IM Not less than 0.5 mg/kg/24 hr.

METHYLPREDNISOLONE ACETATE

ADULTS: IM 40–120 mg q wk for 1–4 wk. Intra-articular/intralesional 4–80 mg into joints or lesions. Topical Apply sparingly to affected areas 2–4 times daily.

Contraindication ::

 Contraindications Systemic fungal infections; idiopathic thrombocytopenic purpura (IM administration); administration of live virus vaccines; topical monotherapy in primary bacterial infections; topical use on face, groin or axilla; use in premature infants (sodium succinate salt).

Drug Precautions ::

 Precautions

Pregnancy: Pregnancy category undetermined (systemic use); Category C (topical use). Lactation: Excreted in breast milk. Children: May be more susceptible to adverse effects from topical use. Benzyl alcohol/gasping syndrome may occur with use of methylprednisolone sodium succinate. Elderly patients: May require lower doses. Adrenal suppression: Prolonged therapy may lead to hypothalamic-pituitary-adrenal suppression. Hepatitis: Drug may be harmful in chronic active hepatitis positive for hepatitis B surface antigen. Hypersensitivity: Reactions, including anaphylaxis, may occur rarely. Immunosuppression: Because drug causes immunosuppressed state, do not administer live virus vaccines during treatment. Infections: May mask signs of infection. May decrease host-defense mechanisms to prevent dissemination of infection. Ocular effects: Use drug systemically with caution in ocular herpes simplex because of risk of possible corneal perforation. Peptic ulcer: Drug may contribute to peptic ulceration, especially in large doses. Repository injections: Do not inject subcutaneously. Avoid injection into deltoid muscle and repeated intramuscular injection into same site. Stress: Increased dosage of rapidly acting corticosteroid may be needed before, during and after stressful situations. Tartrazine sensitivity: May contain tartrazine, which may cause allergic-type reactions in susceptible individuals.

PATIENT CARE CONSIDERATIONS

Drug Side Effects ::

 Adverse Reactions

CV: Thromboembolism or fat embolism; thrombophlebitis; necrotizing angiitis; cardiac arrhythmias or ECG changes; syncopal episodes; hypertension; yocardial rupture; fatal arrest; circulatory collapse; CHF. CNS: Convulsions; pseudotumor cerebri (increased intracranial pressure with papilledema); vertigo; headache; neuritis; paresthesias; psychosis. DERM: Impaired wound healing; thin, fragile skin; petechiae and ecchymoses; rythema; lupus erythematosus-like lesions; subcutaneous fat atrophy; striae; irsutism; acneiform eruptions; allergic dermatitis; urticaria; angioneurotic edema; perineal irritation; hyperpigmentation or hypopigmentation. Topical application: burning; itching; irritation; erythema; dryness; folliculitis; ypertrichosis; pruritus; perioral dermatitis; allergic contact dermatitis; tinging, cracking and tightening of skin; secondary infections; skin atrophy; triae; miliaria; telangiectasia. EENT: Posterior subcapsular cataracts; increased intraocular pressure; glaucoma; xophthalmos. GI: Pancreatitis; abdominal distention; ulcerative esophagitis; nausea; vomiting; ncreased appetite and weight gain; peptic ulcer with perforation and hemorrhage; owel perforation. GU: Increased or decreased motility and number of spermatozoa. HEMA: Leukocytosis. META: Sodium and fluid retention; hypokalemia; hypokalemic alkalosis; etabolic alkalosis; hypocalcemia. OTHER: Musculoskeletal effects (eg, weakness, myopathy, muscle mass loss, osteoporosis, spontaneous fractures); endocrine abnormalities (eg, menstrual irregularities, cushingoid state, growth suppression in children, sweating, decreased carbohydrate tolerance, hyperglycemia, glycosuria, increased insulin or sulfonylurea requirements in diabetic patients, hirsutism); anaphylactoid or hypersensitivity reactions; aggravation or masking of infections; fatigue; nsomnia. Intra-articular administration: Osteonecrosis; tendon rupture; infection; skin atrophy; postinjection flare; hypersensitivity; facial flushing. Topical application may produce adverse reactions seen with systemic use because of absorption.

Drug Mode of Action ::  

 Action Depresses formation, release and activity of endogenous mediators of inflammation including prostaglandins, kinins, histamine, liposomal enzymes and complement system. Modifies body’s immune response.

Drug Interactions ::

 Interactions

Anticholinesterases: May antagonize anticholinesterase effects in myasthenia gravis. Barbiturates: May decrease pharmacologic effect of methylprednisolone. Hydantoins, rifampin: May increase clearance and decrease efficacy of methylprednisolone. Ketoconazole: May decrease clearance of methylprednisolone. Macrolide antibiotics: Significantly decreases methylprednisolone clearance; may need to decrease dose. Salicylates: May reduce serum levels and efficacy of salicylates.

Drug Assesment ::

 Administration/Storage

• When initiating or discontinuing drug therapy, taper dose.
• With oral administration, give with food. Tablets can be crushed and given with fluid.
• Administer once-daily dose or alternate-day dosing in morning before 9 AM.
• Administer multiple doses at evenly spaced intervals throughout day. When large doses are given, administer antacids between meals to help to prevent peptic ulcers. For long-term use, alternate-day regimen may be used.
• With intra-articular injection, inject into synovial space. Do not inject unstable joints.
• When treating conditions such as tendonitis or tenosynovitis, inject into tendon sheath rather than into substance of tendon.
• When treating conditions such as epicondylitis, outline area of greatest tenderness and infiltrate drug into area.
• Advise patient of acne and skin flushing, which are often associated with this medication. Instruct patient in proper skin care practices to help to prevent irritation and/or acne.
• Instruct patient to report these symptoms to physician: swelling in feet and ankles, signs of infection (fever, over-growth in mouth, vaginal yeast, wound not healing or with drainage), diarrhea, nausea, vomiting, weight loss, discolored or painful urine, vision changes, menstrual irregularity and fatigue.

Drug Storage/Management ::

 Administration/Storage

• When initiating or discontinuing drug therapy, taper dose.
• With oral administration, give with food. Tablets can be crushed and given with fluid.
• Administer once-daily dose or alternate-day dosing in morning before 9 AM.
• Administer multiple doses at evenly spaced intervals throughout day. When large doses are given, administer antacids between meals to help to prevent peptic ulcers. For long-term use, alternate-day regimen may be used.
• With intra-articular injection, inject into synovial space. Do not inject unstable joints.
• When treating conditions such as tendonitis or tenosynovitis, inject into tendon sheath rather than into substance of tendon.
• When treating conditions such as epicondylitis, outline area of greatest tenderness and infiltrate drug into area.
• Advise patient of acne and skin flushing, which are often associated with this medication. Instruct patient in proper skin care practices to help to prevent irritation and/or acne.
• Instruct patient to report these symptoms to physician: swelling in feet and ankles, signs of infection (fever, over-growth in mouth, vaginal yeast, wound not healing or with drainage), diarrhea, nausea, vomiting, weight loss, discolored or painful urine, vision changes, menstrual irregularity and fatigue.

Drug Notes ::

 Administration/Storage

• When initiating or discontinuing drug therapy, taper dose.
• With oral administration, give with food. Tablets can be crushed and given with fluid.
• Administer once-daily dose or alternate-day dosing in morning before 9 AM.
• Administer multiple doses at evenly spaced intervals throughout day. When large doses are given, administer antacids between meals to help to prevent peptic ulcers. For long-term use, alternate-day regimen may be used.
• With intra-articular injection, inject into synovial space. Do not inject unstable joints.
• When treating conditions such as tendonitis or tenosynovitis, inject into tendon sheath rather than into substance of tendon.
• When treating conditions such as epicondylitis, outline area of greatest tenderness and infiltrate drug into area.
• Advise patient of acne and skin flushing, which are often associated with this medication. Instruct patient in proper skin care practices to help to prevent irritation and/or acne.
• Instruct patient to report these symptoms to physician: swelling in feet and ankles, signs of infection (fever, over-growth in mouth, vaginal yeast, wound not healing or with drainage), diarrhea, nausea, vomiting, weight loss, discolored or painful urine, vision changes, menstrual irregularity and fatigue.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.